Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Caregivers' willingness-to-pay for Alzheimer's disease medications in Canada.

Oremus M, Tarride JE, Pullenayegum E, Clayton N, Mugford G, Godwin M, Huan A, Bacher Y, Villalpando JM, Gill SS, Lanctôt KL, Herrmann N; Canadian Willingness-To-Pay Study Group, Raina P.

Dementia (London). 2015 Jan;14(1):63-79. doi: 10.1177/1471301213490709. Epub 2013 Jun 5.

PMID:
24339090
2.

Patients' willingness-to-pay for an Alzheimer's disease medication in Canada.

Oremus M, Tarride JE, Pullenayegum E, Clayton N; Canadian Willingness-to-Pay Study Group, Raina P.

Patient. 2013;6(3):161-8. doi: 10.1007/s40271-013-0014-3.

PMID:
23716166
3.

The general public's willingness to pay for tax increases to support unrestricted access to an Alzheimer's disease medication.

Oremus M, Tarride JE, Raina P, Thabane L, Foster G, Goldsmith CH, Clayton N.

Pharmacoeconomics. 2012 Nov 1;30(11):1085-95. doi: 10.2165/11594180-000000000-00000.

PMID:
22938161
4.

Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada.

Oremus M, Tarride JE, Clayton N, Raina P.

BMC Health Serv Res. 2009 Dec 29;9:246. doi: 10.1186/1472-6963-9-246.

5.

The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Wu G, Lanctôt KL, Herrmann N, Moosa S, Oh PI.

CNS Drugs. 2003;17(14):1045-57.

PMID:
14594444
6.

Caregiver acceptance of adverse effects and use of cholinesterase inhibitors in Alzheimer's disease.

Oremus M, Wolfson C, Vandal AC, Bergman H, Xie Q.

Can J Aging. 2007 Fall;26(3):205-12. doi: 10.3138/cja.26.3.205.

PMID:
18238727
7.

Canadian Alzheimer's disease caregiver survey: baby-boomer caregivers and burden of care.

Black SE, Gauthier S, Dalziel W, Keren R, Correia J, Hew H, Binder C.

Int J Geriatr Psychiatry. 2010 Aug;25(8):807-13. doi: 10.1002/gps.2421.

PMID:
20029824
8.

Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease.

Gustavsson A, Jönsson L, McShane R, Boada M, Wimo A, Zbrozek AS.

Int J Geriatr Psychiatry. 2010 Jun;25(6):622-32. doi: 10.1002/gps.2385.

PMID:
19750558
9.

Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.

Yatabe Y, Hashimoto M, Kaneda K, Honda K, Ogawa Y, Yuuki S, Ikeda M.

Psychogeriatrics. 2013 Jun;13(2):88-93. doi: 10.1111/psyg.12004.

10.

The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients.

Beeri MS, Werner P, Davidson M, Noy S.

Int J Geriatr Psychiatry. 2002 May;17(5):403-8.

PMID:
11994927
11.

Economic analysis of the intangible impacts of informal care for people with Alzheimer's disease and other mental disorders.

Gervès C, Bellanger MM, Ankri J.

Value Health. 2013 Jul-Aug;16(5):745-54. doi: 10.1016/j.jval.2013.03.1629. Epub 2013 Jun 15.

12.

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.

Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, Kent DM.

Health Econ. 2012 Mar;21(3):238-51. doi: 10.1002/hec.1704. Epub 2010 Dec 28.

PMID:
22271512
13.

Caregivers' assessments of preference-based quality of life in Alzheimer's disease.

Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Low DV, Glick HA.

Alzheimers Dement. 2008 May;4(3):203-11. doi: 10.1016/j.jalz.2007.11.018. Epub 2008 Apr 24.

PMID:
18631969
14.

Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.

Baladi JF, Bailey PA, Black S, Bouchard RW, Farcnik KD, Gauthier S, Kertesz A, Mohr E, Robillard A.

Clin Ther. 2000 Dec;22(12):1549-61.

PMID:
11192146
15.

Reduction of caregiver burden in Alzheimer's disease by treatment with galantamine.

Kaufer DI, Borson S, Kershaw P, Sadik K.

CNS Spectr. 2005 Jun;10(6):481-8. Review.

PMID:
15908902
16.

The contingency of contingent valuation. How much are people willing to pay against Alzheimer's disease?

Nocera S, Bonato D, Telser H.

Int J Health Care Finance Econ. 2002 Sep;2(3):219-40.

PMID:
14625942
17.

Willingness of families caring for victims of dementia to pay for nursing home care: results of a pilot study in Taiwan.

Chiu L, Tang KY, Liu YH, Shyu WC, Chang TP.

J Manag Med. 1998;12(6):349-60, 321.

PMID:
10351260
18.

Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale.

Matsui T, Nakaaki S, Murata Y, Sato J, Shinagawa Y, Tatsumi H, Furukawa TA.

Dement Geriatr Cogn Disord. 2006;21(3):182-91. Epub 2006 Jan 9.

PMID:
16401890
19.
20.

Mutual altruism: evidence from Alzheimer patients and their spouse caregivers.

König M, Pfarr C, Zweifel P.

Adv Health Econ Health Serv Res. 2014;24:141-60.

PMID:
25244908

Supplemental Content

Support Center